A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2011
11/24/2011	US20110286926 Degradable hydrogel compositions and methods
11/24/2011	US20110286925 Embolizing Sclerosing Hydrogel
11/24/2011	US20110286924 Novel human endogenous retroviral erv3 variant and uses thereof in the diagnosing ovarian cancer
11/24/2011	US20110286919 Conjugates of noscapine and folic acid and their use in treating cancer
11/24/2011	US20110286918 Immunotherapy of autoimmune disorders using antibodies which target b-cells
11/24/2011	US20110286917 Novel, Prostate-Specific Gene for Diagnosis, Prognosis and Management of Prostate Cancer
11/24/2011	US20110286915 Nanocarriers for Drug Delivery
11/24/2011	CA2837494A1 Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal
11/24/2011	CA2836315A1 Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas
11/24/2011	CA2816928A1 Vitamin e conjugates, and their uses as antioxidants and prodrug delivery vehicles
11/24/2011	CA2800220A1 Phenylmorpholines and analogues thereof
11/24/2011	CA2800219A1 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
11/24/2011	CA2800161A1 Modulators of 5-ht receptors and methods of use thereof
11/24/2011	CA2800143A1 Selective hdac inhibitors
11/24/2011	CA2800109A1 Methods for inhibiting muscle atrophy
11/24/2011	CA2800094A1 Liquid nasal spray containing low-dose naltrexone
11/24/2011	CA2800079A1 Macrocyclic compounds as trk kinase inhibitors
11/24/2011	CA2800018A1 Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders
11/24/2011	CA2800015A1 Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
11/24/2011	CA2799989A1 Polycyclic quinazolines, preparation thereof, and use thereof
11/24/2011	CA2799944A1 Methods and compositions related to modulating autophagy
11/24/2011	CA2799942A1 Pharmaceutical composition containing solifenacin
11/24/2011	CA2799937A1 Processes for preparing macrolides and ketolides and intermediates therefor
11/24/2011	CA2799928A1 Topical formulation for a jak inhibitor
11/24/2011	CA2799904A1 Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
11/24/2011	CA2799820A1 Posology and administration of glucocorticoid based compositions
11/24/2011	CA2799792A1 Inhibitors of human 12-lipoxygenase
11/24/2011	CA2799779A1 Piperidinyl-substituted lactams as gpr119 modulators
11/24/2011	CA2799764A1 Mtor selective kinase inhibitors
11/24/2011	CA2799762A1 Crystalline hydrochloride salt of darunavir
11/24/2011	CA2799744A1 A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
11/24/2011	CA2799708A1 2-phenyl benzoylamides
11/24/2011	CA2799666A1 Stable ready to use injectable paracetamol formulation
11/24/2011	CA2799633A1 Improved anti-serum albumin binding variants
11/24/2011	CA2799621A1 Compositions for the treatment of gynaecological disorders
11/24/2011	CA2799579A1 Chemical compounds, compositions and methods for kinase modulation
11/24/2011	CA2799559A1 Production of dha and other lc-pufas in plants
11/24/2011	CA2799556A1 Compounds
11/24/2011	CA2799531A1 Methods of treating recurring bacterial infection
11/24/2011	CA2799517A1 Method for purifying a fused pyrrolocarbazole derivative
11/24/2011	CA2799491A1 Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient
11/24/2011	CA2799414A1 Spiro isoxazoline compounds as sstr5 antagonists
11/24/2011	CA2799393A1 Skin preparation composition for external use with excellent antibacterial and antifungal effects
11/24/2011	CA2799390A1 Prodrug of triazolone compound
11/24/2011	CA2799386A1 Treatment of clostridium difficile infection in patients undergoing antibiotic therapy
11/24/2011	CA2799337A1 Compounds
11/24/2011	CA2798970A1 Pyrrolopyrazine derivatives as syk and jak inhibitors
11/24/2011	CA2798911A1 Theobromine for increasing hdl-cholesterol
11/24/2011	CA2798735A1 Prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis
11/24/2011	CA2792669A1 Long - acting formulations of insulins
11/24/2011	CA2790170A1 Treatment for altitudinal hypoxia
11/23/2011	EP2388326A1 Modulation of glucagon receptor expression
11/23/2011	EP2388315A2 Use of a combination of myxoma virus and rapamycin for therapeutic treatment
11/23/2011	EP2388263A1 Imidazo[2,1-b]thiazole derivatives as sirtuin modulators
11/23/2011	EP2388259A1 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
11/23/2011	EP2388258A1 Novel vanilloid receptor ligands and their use for producing medicaments
11/23/2011	EP2388255A1 Polysubstituted benzofurans and medicinal applications thereof
11/23/2011	EP2388250A1 4-Pyrimidinone derivatives and their use as anti-HIV agents
11/23/2011	EP2388249A1 HIV inhibiting 2-(4-cyanophenylamino) pyrimidine derivatives
11/23/2011	EP2388248A1 Methods for the preparation of ivabradine sulfate and form i crystal thereof
11/23/2011	EP2388247A2 Histone deacetylase inhibitors
11/23/2011	EP2388245A1 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
11/23/2011	EP2388009A1 Dermatological composition containing avermictin nanocapsules, method for preparing the same and uses thereof
11/23/2011	EP2388008A1 Stable, preservative-free, aqueous formulation for the administration by aerosolization comprising tobramycin
11/23/2011	EP2388007A1 Compounds, formulations, and methods for treating or preventing rosacea
11/23/2011	EP2388006A1 Urea derivatives as IL-8 receptor antagonists
11/23/2011	EP2388005A1 Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
11/23/2011	EP2388004A1 Salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine
11/23/2011	EP2388003A2 Colchicine derivatives
11/23/2011	EP2388002A2 Antidepressant containing heterocyclic compound having specific structure
11/23/2011	EP2388001A2 Age retardant containing heterocyclic compound having specific structure
11/23/2011	EP2388000A2 Neuroprotectant containing heterocyclic compound having specific structure
11/23/2011	EP2387999A1 Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
11/23/2011	EP2387998A1 Methods for treating degenerative diseases/injuries
11/23/2011	EP2387997A1 Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients who developed permanent atrial fibrillation throughout the period the dronedarone is administered
11/23/2011	EP2387996A1 Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
11/23/2011	EP2387995A1 Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
11/23/2011	EP2387993A1 Orally disintegrating tablets of zolmitriptan and process for preparing the same
11/23/2011	EP2387992A1 Improvements relating to nanodispersions
11/23/2011	EP2387991A1 Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
11/23/2011	EP2387990A1 Topical composition and use thereof for the prophylaxis and the treatment of defects connected to inflammatory dermopathies
11/23/2011	EP2387612A1 Method of inhibiting proliferation of hepatic stellate cells
11/23/2011	EP2387611A1 Diagnosis and treatment of autism spectrum disorders
11/23/2011	EP2387577A2 Non-peptidyl, potent, and selective mu opioid receptor antagonists
11/23/2011	EP2387575A1 Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
11/23/2011	EP2387574A1 Oxadiazole beta carboline derivatives as antidiabetic compounds
11/23/2011	EP2387573A1 6-phenyl-lh-imidazo ý4, 5-c¨pyridine-4-carbonitrile derivatives as cathepsin s and/or cathepsin k inhibitors
11/23/2011	EP2387572A2 Protein kinase c inhibitors and uses thereof
11/23/2011	EP2387571A1 Oxadiazole derivatives as slpl receptor agonists
11/23/2011	EP2387570A1 Fluoroisoquinoline substituted thiazole compounds and methods of use
11/23/2011	EP2387568A1 Novel benzotriazole derivatives useful for the treatment of cns disorders
11/23/2011	EP2387567A2 Methods for screening and compounds that protect against amyloid diseases
11/23/2011	EP2387565A2 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders
11/23/2011	EP2387564A1 Benzo ýc¨phenanthridines as antimicrobial agents
11/23/2011	EP2387563A1 Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
11/23/2011	EP2387562A1 Quinolinone derivatives useful for the treatment of cns disorders
11/23/2011	EP2387560A2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
11/23/2011	EP2387559A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
11/23/2011	EP2387440A2 Quinazolinone derivatives useful as vanilloid antagonists
11/23/2011	EP2387409A1 Chitosan derivatives alone or in combination for the treatment of mdr microbial infections

1 ... 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 ... 7860